A variety of therapeutic agents have been delivered to canine brain tumors, the majority of which have been gliomas, via CED, including liposomal CPT-11 and nanoparticle-based temozolomide chemotherapies, targeted nanoparticular agents (EGFR-antibody bioconjugated nanoparticles), and recombinant bacterial cytotoxins and chemotherapeutic conjugates targeting the EphA2, EphA3, EphB2, and IL-13RA2 receptors that are overexpressed in canine gliomas (74, 77, 82–84). This evidence concerns the gene EGFR and brain neoplasm.